EXPERT REACTION: TGA approves first oral treatments for COVID-19
Not peer-reviewed: This work has not been scrutinised by independent experts, or the story does not contain research data to review (for example an opinion piece). If you are reporting on research that has yet to go through peer-review (eg. conference abstracts and preprints) be aware that the findings can change during the peer review process.
Opinion piece/editorial: This work is based on the opinions of the author(s)/institution.
Opinion piece/editorial: This work is based on the opinions of the author(s)/institution.
The antiviral treatments, molnupiravir (Lagevrio) and the combination of nirmatrelvir and ritonavir (Paxlovid) have been approved by the Therapeutic Goods Administration (TGA) for the treatment of COVID-19 in Australia. The prescription-only medicines are designed to be taken twice a day for five days and they work by reducing the virus's ability to rapidly multiply. The medical regulator said the treatments are not a substitute for the COVID-19 vaccine. Below Australian experts explain how the drugs will be used in Australia.
Organisation/s: Australian Science Media Centre
Funder: N/A
News for:
Australia
VIC
QLD
SA
WA
Media contact details for this story are only visible to registered journalists.
Expert Reaction
These comments have been collated by the Science Media Centre to provide a variety of expert perspectives on this issue. Feel free to use these quotes in your stories. Views expressed are the personal opinions of the experts named. They do not represent the views of the SMC or any other organisation unless specifically stated.